Eagle Asset Management Inc. increased its position in shares of AveXis, Inc. (NASDAQ:AVXS) by 41.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 158,528 shares of the company’s stock after acquiring an additional 46,835 shares during the quarter. Eagle Asset Management Inc. owned about 0.50% of AveXis worth $15,180,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC increased its holdings in AveXis by 13.1% in the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after purchasing an additional 544,475 shares during the last quarter. BlackRock Inc. increased its holdings in AveXis by 34.7% in the second quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after purchasing an additional 592,843 shares during the last quarter. Vanguard Group Inc. increased its holdings in AveXis by 31.8% in the second quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after purchasing an additional 380,396 shares during the last quarter. State Street Corp increased its holdings in AveXis by 104.2% in the second quarter. State Street Corp now owns 1,000,001 shares of the company’s stock valued at $82,163,000 after purchasing an additional 510,189 shares during the last quarter. Finally, Janus Henderson Group PLC bought a new stake in AveXis in the second quarter valued at about $55,439,000. 92.88% of the stock is currently owned by institutional investors and hedge funds.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $101.26, for a total value of $180,242.80. Following the completion of the sale, the vice president now directly owns 1,780 shares in the company, valued at $180,242.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian K. Kaspar sold 15,000 shares of the stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $101.46, for a total value of $1,521,900.00. The disclosure for this sale can be found here. Insiders sold 33,560 shares of company stock valued at $3,393,698 over the last 90 days. Corporate insiders own 18.60% of the company’s stock.

AVXS has been the subject of a number of recent analyst reports. Barclays initiated coverage on AveXis in a report on Wednesday, September 6th. They issued an “overweight” rating and a $124.00 price objective for the company. Nomura initiated coverage on AveXis in a report on Monday, August 28th. They issued a “reduce” rating and a $52.00 price objective for the company. Zacks Investment Research upgraded AveXis from a “hold” rating to a “buy” rating and set a $112.00 price objective for the company in a report on Tuesday, October 24th. Instinet initiated coverage on AveXis in a report on Tuesday, August 29th. They issued a “reduce” rating and a $52.00 price objective for the company. Finally, Bank of America dropped their price objective on AveXis from $115.00 to $112.00 and set a “buy” rating for the company in a report on Friday, November 10th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $110.67.

Shares of AveXis, Inc. (NASDAQ AVXS) opened at $94.81 on Friday. AveXis, Inc. has a fifty-two week low of $44.68 and a fifty-two week high of $108.27.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.48) by ($0.04). During the same period in the prior year, the company posted ($0.87) earnings per share. analysts predict that AveXis, Inc. will post -6.23 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Eagle Asset Management Inc. Raises Stake in AveXis, Inc. (AVXS)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/02/eagle-asset-management-inc-raises-stake-in-avexis-inc-avxs.html.

AveXis Company Profile

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis, Inc. (NASDAQ:AVXS).

Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.